业绩亮眼，百奥赛图AH股齐创历史新高

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a year-on-year growth of 384.26% to 443.88%, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [1]. Group 1 - The company's net profit attributable to shareholders is forecasted to be between 162 million to 182 million yuan for 2025 [1]. - A-share prices surged over 18% to reach a new high of 78.75 yuan, while H-share prices increased by over 43% to 63 Hong Kong dollars, also marking a new high [1]. - The company's high technical barriers ensure that gross margins remain elevated, and lean management practices further enhance operational efficiency, contributing to rapid profit growth [1].